Stephens Inc. AR Has $232,000 Stock Position in Solventum Corporation (NYSE:SOLV)

Stephens Inc. AR lowered its position in shares of Solventum Corporation (NYSE:SOLV) by 11.5% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,053 shares of the company’s stock after selling 396 shares during the quarter. Stephens Inc. AR’s holdings in Solventum were worth $232,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SOLV. Clarity Asset Management Inc. bought a new stake in shares of Solventum during the 4th quarter worth approximately $25,000. Rossby Financial LCC bought a new stake in Solventum in the 1st quarter valued at $25,000. Raiffeisen Bank International AG bought a new stake in Solventum in the 4th quarter valued at $29,000. Colonial Trust Co SC raised its stake in Solventum by 240.7% in the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company’s stock valued at $34,000 after acquiring an additional 361 shares during the period. Finally, Hara Capital LLC bought a new stake in Solventum in the 1st quarter valued at $38,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on SOLV shares. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $80.00 to $103.00 in a research note on Tuesday, July 15th. KeyCorp started coverage on Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating on the stock. Piper Sandler upgraded Solventum from a “neutral” rating to an “overweight” rating and increased their price target for the company from $78.00 to $87.00 in a research note on Monday, May 19th. Finally, Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a research note on Tuesday, July 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $84.38.

Solventum Stock Performance

Shares of NYSE SOLV opened at $73.29 on Monday. The company has a debt-to-equity ratio of 2.40, a current ratio of 1.19 and a quick ratio of 0.85. The stock’s fifty day moving average price is $74.19 and its two-hundred day moving average price is $72.76. Solventum Corporation has a one year low of $53.03 and a one year high of $85.92. The firm has a market cap of $12.68 billion, a price-to-earnings ratio of 33.93, a P/E/G ratio of 1.88 and a beta of 0.55.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.15. The company had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. Solventum had a return on equity of 31.01% and a net margin of 4.55%. Solventum’s quarterly revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.08 EPS. On average, equities analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.